Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

51 results about "KLK5" patented technology

Kallikrein-related peptidase 5 (KLK5), formerly known as stratum corneum tryptic enzyme (SCTE), is a serine protease expressed in the epidermis. In humans it is encoded by the KLK5 gene. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its expression is up-regulated by estrogens and progestins. Alternative splicing results in multiple transcript variants encoding the same protein.

KLK5 / 7 + th2 targeting antibodies and uses thereof

Aspects of the application provide bispecific antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis. In some embodiments, the bispecific antibody comprises at least one antigen-specific binding site that specifically binds KLK5 and KLK7 and at least one antigen-specific binding site that specifically binds to a Th2 cytokine (e.g., IL-13) or receptor thereof.
Owner:TRIVENI BIO INC

Triple compound acid composition with skin brightening and acne removing effects, product and application of triple compound acid composition

The invention belongs to the technical field of daily chemistry, and provides a triple compound acid composition with skin brightening and acne removing effects, a product and application of the triple compound acid composition and the product, the triple compound acid composition comprises mandelic acid, salicylic acid and succinic acid, and the mass ratio of the mandelic acid to the salicylic acid to the succinic acid is (3-6): (1-2): (1-2). The invention further provides a product containing the composition and application of the product. The composition provided by the invention is synergistically used, has a synergistic effect in the aspect of exfoliating, especially in the aspect of improving the activity of kallikrein 5 (KLK5), not only has the effects of biological skin glowing and exfoliating, but also can efficiently down-regulate the expression of I-type 5alpha-reductase genes, so that the synthesis of sebum is inhibited, and an oil control effect is achieved; in addition, the composition provided by the invention has the effects of brightening, inhibiting bacteria and resisting inflammation, has low sensitization, can be used for removing acnes, takes effect quickly and does not relapse.
Owner:GUANGZHOU JIYAN COSMETICS TECH CO LTD

Compositions and methods for treating allergic inflammatory conditions

Provided are methods for increasing SPINK7 anti-proteinase activity in a target tissue of a subject having an allergic inflammatory condition characterized by inflammation of a squamous epithelium in the target tissue, the method comprising inhibiting kallikrein 5 (KLK5) proteinase activity in the target tissue. Suitable KLK5 inhibitors may include a KLK5-Fc fusion protein, a KLK5 anti-sense polynucleotide, a KLK5-directed miRNA, a KLK5-directed shRNA, a KLK5-directed antibody, or a coumarin compound such as 3-(3-chlorophenyl) carboxy-7-hydroxymethyl coumarin or 3-carboxy-7-hydroxymethyl coumarin.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI

Cutin regulating composition containing mandelic acid and having skin smoothing and brightening effects and application thereof

The invention belongs to the technical field of daily-use chemistry, and particularly relates to a keratin regulating composition containing mandelic acid and having skin smoothing and brightening effects and application of the keratin regulating composition. The composition provided by the invention comprises mandelic acid, lactobionic acid, hydroxyethyl piperazine ethanesulfonic acid, lactobacillus / soybean milk fermentation product filtrate and lactobacillus fermentation lysate. According to the application, mandelic acid, lactobionic acid, hydroxyethyl piperazine ethanesulfonic acid, lactobacillus / soybean milk fermentation product filtrate and lactobacillus fermentation lysate are compounded, so that the activity of KLK family proteases, especially kallikrein 5 (KLK5), can be obviously promoted, the decomposition of desmosome between keratinocytes is promoted, epidermal cells lose cohesion and finally naturally fall off, and the effect of promoting the activity of KLK family proteases is achieved. The cutin exfoliation promoting effect is achieved, so that the problems of skin darkness, roughness, pore blockage, acne and the like are solved, the glossiness and fineness of the skin are improved, and healthy and bright skin is achieved.
Owner:GUANGZHOU JIYAN COSMETICS TECH CO LTD

Klk5 / 7 + th2 targeting antibodies and uses thereof

Aspects of the application provide bispecific antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis. In some embodiments, the bispecific antibody comprises at least one antigen-specific binding site that specifically binds KLK5 and KLK7 and at least one antigen-specific binding site that specifically binds to a Th2 cytokine (e.g., IL-13) or receptor thereof.
Owner:TRIVENI BIO INC

KLK5 / 7 + il-4 targeting antibodies and uses thereof

Aspects of the application provide bispecific antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis. In some embodiments, the bispecific antibody comprises at least one antigen-specific binding site that specifically binds KLK5 and KLK7 and at least one antigen-specific binding site that specifically binds to IL-4 or receptor thereof.
Owner:TRIVENI BIO INC

KLK5 / 7 + ox40 targeting antibodies and uses thereof

Aspects of the application provide bispecific antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis. In some embodiments, the bispecific antibody comprises at least one antigen- specific binding site that specifically binds KLK5 and KLK7 and at least one antigen- specific binding site that specifically binds to OX40L or receptor thereof.
Owner:TRIVENI BIO INC

Dual inhibitor kallikrein antibodies and uses thereof

Aspects of the application provide dual inhibitor anti-KLK5 / KLK7 antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis.
Owner:TRIVENI BIO INC

Benzoxazinone compounds as dual KLK5 / 7 inhibitors

Owner:MOLECULAR SKIN THERAPEUTICS INC

KLK5 / 7+TH2 targeted antibody and its use

Aspects of this application provide bispecific antibodies and methods of using them for treating conditions such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis, by promoting barrier function and reducing inflammation. In some embodiments, the bispecific antibody includes at least one antigen-specific binding site that specifically binds to KLK5 and KLK7, and at least one antigen-specific binding site that specifically binds to a Th2 cytokine (e.g., IL-13) or its receptor.
Owner:トリヴェニ バイオ インコーポレイテッド

KLK5 / 7 + il-13 targeting antibodies and uses thereof

Aspects of the application provide bispecific antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis. In some embodiments, the bispecific antibody comprises at least one antigen-specific binding site that specifically binds KLK5 and KLK7 and at least one antigen-specific binding site that specifically binds to IL-13 or receptor thereof.
Owner:TRIVENI BIO INC

Fusion protein inhibitors of KLK5

Disclosed herein are polypeptides that are useful for, among other things, inhibiting or suppressing the activity of a kallikrein-related protease and therefore treating diseases and conditions involving dysregulated kallikrein-related protease activity. Pharmaceutical compositions and therapeutic methods using the polypeptides and pharmaceutical compositions are also provided.
Owner:BIOCRYST PHARMACEUTICALS INC

A recombinant humanized filaggrin and its uses

The present invention discloses a recombinant humanized filaggrin and its uses. The recombinant humanized filaggrin contains a humanized LEKTI protein fragment, and the humanized LEKTI protein fragment contains the humanized Kazal motif protein sequence shown in SEQ ID No.2; it also contains a humanized FLG protein fragment, and the humanized FLG protein fragment is linked to the humanized LEKTI protein fragment through a linker containing a furin cleavage site. After cleavage by interstitial furin protease, the two protein fragments perform their respective functions. The recombinant humanized filaggrin of the present invention has the prospect of being developed into a drug, a cosmetic or a medical device for treating diseases that can be treated or alleviated by supplementing FLG and / or inhibiting kallikrein KLK5. Diseases that can be treated or alleviated by supplementing FLG and / or inhibiting KLK5 include atopic dermatitis, Netherton syndrome and tumors with high expression of KLKs.
Owner:HUNAN ZHONGKEJIMEI BIOTECHNOLOGY CO LTD

Tricyclic heteroaromatic inhibitors of KLK5

PCT designated stage expiredWO2025049326A1Organic chemistryDermatological disorderDiseaseNetherton syndrome
Disclosed are tricyclic heteroaromatic compounds of formulae (I) and (II), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant KLK5 activity activity, such as Netherton Syndrome. Formulae (I) and (II)
Owner:BIOCRYST PHARMACEUTICALS INC

Klk5 / 7 + il-13 targeting antibodies and uses thereof

Aspects of the application provide bispecific antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis. In some embodiments, the bispecific antibody comprises at least one antigen-specific binding site that specifically binds KLK5 and KLK7 and at least one antigen-specific binding site that specifically binds to IL-13 or receptor thereof.
Owner:TRIVENI BIO INC

Kallikrein antibodies and their use

Aspects of this application provide anti-KLK5 antibodies, anti-KLK7 antibodies, and anti-KLK5 / KLK7 antibodies (e.g., bispecific antibodies), as well as methods of using them to promote barrier function, reduce inflammation, and treat conditions such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis. Certain aspects of this disclosure relate to the recognition that a loss of balance between endogenous KLK proteases and associated protease inhibitors can lead to barrier dysfunction and induce inflammation (see, for example, Figure 1), which can result in inflammatory conditions, such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis.
Owner:トリヴェニ バイオ インコーポレイテッド

Anti-KLK7 antibodies, Anti-KLK5 antibodies, multispecific Anti-KLK5 / KLK7 antibodies and methods of use

To provide anti-KLK7 antibody, anti-KLK5 antibody, multispecific anti-KLK5 / KLK7 antibody and methods of use.SOLUTION: The disclosure provides an isolated antibody that binds to human kallikrein related peptidase 7 (KLK7), where the antibody inhibits human KLK7-mediated cleavage of a substrate of a certain amino acid sequence, and / or binds to human KLK7 with a KD of less than 10 pM, or less than 9 pM, or less than 8 pM, or less than 7 pM, or less than 6 pM, or less than 5 pM as measured by surface plasmon resonance, and the antibody binds to a specific epitope of KLK7.SELECTED DRAWING: Figure 19B
Owner:GENENTECH INC

Triple complex acid composition with skin lightening and acne-fighting efficacy, products and uses thereof

The application belongs to the technical field of daily chemicals, and provides a triple composite acid composition with skin lightening, skin rejuvenation and acne-removing effects, a product and application thereof, which comprises almond acid, salicylic acid and succinic acid, and the mass ratio of the almond acid, the salicylic acid and the succinic acid is 3-6:1-2:1-2. The application also provides a product containing the above composition and application thereof. The composition provided by the application is synergistically used, has a synergistic effect in terms of exfoliation, especially in terms of improving the activity of kallikrein 5 (KLK5), has not only the effects of biological skin rejuvenation and exfoliation, but also can efficiently down-regulate the expression of I-type 5alpha-reductase gene, thereby inhibiting the synthesis of sebum and playing an oil control role. In addition, the composition provided by the application has the effects of lightening, bacteriostasis and anti-inflammation, has low sensitization, can be used for acne removal, has rapid effect and is not repeated.
Owner:GUANGZHOU JIYAN COSMETICS TECH CO LTD

Fusion protein inhibitors of KLK5

The present invention discloses polypeptides useful, inter alia, for inhibiting or suppressing the activity of trypsin-associated proteases, and thus treating diseases and conditions involving a disorder of trypsin-associated protease activity. Pharmaceutical compositions and methods of treatment using the polypeptides and pharmaceutical compositions are also provided.
Owner:BIOCRYST PHARMACEUTICALS INC

Anti- KLK7 antibodies, Anti- KLK5 antibodies, multispecific Anti- KLK5 / KLK7 antibodies and methods of use

To provide anti- KLK7 antibodies, anti- KLK5 antibodies, anti- KLK5 / KLK7 multispecific antibodies, and methods of using the same.SOLUTION: Provided are isolated antibodies that bind to human kallikrein-related peptidase-7 (KLK7), wherein the antibodies inhibit human KLK7 mediated cleavage of a substrate comprising a particular amino acid sequence, and / or wherein the antibodies bind to human 10pM with a KD less than 9pM, or less than, or less than 8pM, or less than 7pM, or less than 6pM, or less than 5pM, and wherein the antibodies bind to a particular epitope of KLK7. KLK7.SELECTED DRAWING: Figure 19B
Owner:GENENTECH INC

Compounds and methods for treating cancer, viral infections, and allergic conditions

The present invention generally relates to compounds that are useful for inhibiting one or more trypsin-like S1 serine proteases, HGFA, matriptase, hepsin, KLK5 and / or TMPRSS2 as well as cysteine proteases including trypsin-like cysteine proteases (e.g. Cathepsin B). The present invention also relates to various methods of using the inhibitor compounds to treat or prevent viral infections, including those caused by coronaviruses and influenza, conditions associated with KLK5, various malignancies, pre-malignant conditions, and cancer.
Owner:WASHINGTON UNIV IN SAINT LOUIS

Benzoxazinone compounds as KLK5 / 7 dual inhibitors

PendingAU2020359526B2DiseaseMedicine
The present invention provides compounds and pharmaceutical compositions including the compounds for the treatment of a skin disease associated with proteolytic activity of one or more KLK proteases, wherein the compounds are according to formula (I): wherein R is as described herein.
Owner:MOLECULAR SKIN THERAPEUTICS INC

Klk5 inhibitor and method for producing the same

To provide a novel peptide.SOLUTION: A peptide contains the amino acid sequence represented by SEQ ID NO:61 and inhibits protease.SELECTED DRAWING: None
Owner:DAIICHI SANKYO CO LTD

Benzoxazinone compounds as KLK5 / 7 dual inhibitors

The present invention provides compounds and pharmaceutical compositions including the compounds for the treatment of a skin disease associated with proteolytic activity of one or more KLK proteases, wherein the compounds are according to formula (I):wherein R is as described herein.
Owner:MOLECULAR SKIN THERAPEUTICS INC

Dual inhibitory kallikrein antibody and its use

Aspects of this application provide dual inhibitory anti-KLK5 / KLK7 antibodies and methods of using them to promote barrier function, reduce inflammation, and treat conditions such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis. Certain aspects of this disclosure relate to the recognition that a loss of balance between endogenous KLK proteases and associated protease inhibitors can lead to barrier dysfunction and induce inflammation (see, for example, Figure 1), which can result in inflammatory conditions, such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis.
Owner:トリヴェニ バイオ インコーポレイテッド